Dear Ms Jeandron,

In accordance with exchanges between your entity and the World Health Organization (WHO) last year, the WHO Executive Board reviewed the report of our relations and collaboration at its 142th session in January 2018.

I am pleased to inform you that the WHO Executive Board decided to maintain the Humatem in official relations with WHO. In making the decision, the Executive Board commended your continuing dedication in supporting the work of WHO. Please find attached a copy of the decision (Document EB142 (9)).

I would like to take this opportunity to convey my thanks to the Humatem for its work with WHO. Please contact Mrs A. Velazquez Berumen, who serves as the designated technical officer (DTO) for our relations, to pursue implementation of the agreed plan for collaboration.

Kindly note that the review of the implementation of that plan will take place by the Executive Board in January 2021, according to the triennial schedule for reviews.

Should you have any queries about our formal relations, please do not hesitate to contact the Department of Partnerships and Non-State Actors at nonstateactors@who.int.

I look forward to the continuing support and collaboration of your entity in implementing activities to achieve global health goals.

Yours sincerely,

Dr Gaudenz Silberschmidt
Director
Partnerships and Non-State Actors
Office of the Director-General

09 February 2018
Engagement with non-State actors

The Executive Board, having examined the report on non-State actors in official relations with WHO, including the review of one third of the non-State actors in official relations with WHO,1

(1) decided:

(a) to admit into official relations with WHO the following non-State actors: Association Africaine des Centrales d’Achats de Médicaments Essentiels; Bloomberg Family Foundation, Inc.; Childhood Cancer International; International Society of Paediatric Oncology; IOGT International; KNCV Tuberculosis Foundation; Médecins du Monde; Osteopathic International Alliance; PATH; Public Services International; The Wellcome Trust; and United States Pharmacopeia Convention;

(b) to discontinue official relations with the following non-State actors: European Centre for Ecotoxicology and Toxicology of Chemicals; Foundation for Innovative New Diagnostics; International Federation of Business and Professional Women; and Rehabilitation International;

(2) noted with appreciation their collaboration with WHO, commended their continuing dedication to the work of WHO, and decided to renew in official relations with WHO the 66 non-State actors whose names are listed in Annex 2 to document EB142/29;

(3) further noted that plans for collaboration with the following entities have yet to be agreed, and decided to defer the review of relations with CBM; CropLife International; International Agency for the Prevention of Blindness; International Air Transport Association; International Association for the Study of Pain; International Eye Foundation; International Network for Cancer Treatment and Research; International Society of Physical and Rehabilitation Medicine; Project ORBIS International, Inc.; World Blind Union; and World Council of Optometry until the 144th session of the Board in January 2019, at which time reports should be presented to the Board on the agreed plans for collaboration and on the status of relations.

(Twelfth meeting, 26 January 2018)

1 Document EB142/29.